Genmab A GMAB
NASDAQ GMAB
$39.46 +0.39 (+0.99%)
As of: Oct 21, 2026 · 2:08 PM EDT

Genmab A (GMAB) Restructuring Costs (2024 - 2026)

Updated

Genmab A's Restructuring Costs was -$32 million in the quarter ended Jun 30, 2026.

Analysis

Genmab A (GMAB) Restructuring Costs (2024 - 2026) Analysis & Trends

On a trailing twelve-month basis, Genmab A's Restructuring Costs was -$120 million through Jun 30, 2026; for the year ended Dec 31, 2025, it came in at -$185 million.

  • In earlier years, Restructuring Costs was -$43 million in the year ended Dec 31, 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,133.90 Bn 1,102.48 Bn 19.71 Bn
2 Johnson & Johnson 616.46 Bn 534.99 Bn 17.26 Bn
3 AbbVie 501.26 Bn 474.37 Bn 12.70 Bn
4 Merck 367.00 Bn 321.38 Bn 12.21 Bn
5 Novartis Ag 297.91 Bn 261.90 Bn 11.24 Bn
6 Astrazeneca 261.33 Bn 235.02 Bn 12.86 Bn
7 Amgen 235.82 Bn 191.22 Bn 7.24 Bn
8 Gilead Sciences 190.63 Bn 164.82 Bn 6.22 Bn
9 Pfizer 169.35 Bn 115.99 Bn 10.94 Bn
10 Genmab A 2.55 Bn -2.82 Bn 1.07 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.00 Mn
Mar 31, 2026 -45.00 Mn
Dec 31, 2024 -43.00 Mn
Sep 30, 2024 -3.00 Mn
Jun 30, 2024 -25.00 Mn
API Access

Genmab A Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=GMAB&period=max&api_key=YOUR_API_KEY